Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 9/2014

01-12-2014 | Original Paper

Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain

Authors: Álvaro Hidalgo-Vega, Juan Manuel Ramos-Goñi, Renata Villoro

Published in: The European Journal of Health Economics | Issue 9/2014

Login to get access

Abstract

Background

Ranolazine is an antianginal agent that was approved in the EU in 2008 as an add-on therapy for symptomatic chronic angina pectoris treatment in patients who are inadequately controlled by, or are intolerant to, first-line antianginal therapies. These patients’ quality of life is significantly affected by more frequent angina events, which increase the risk of revascularization.

Objective

To assess the cost-utility of ranolazine versus placebo as an add-on therapy for the symptomatic treatment of patients with chronic angina pectoris in Spain.

Methods

A decision tree model with 1-year time horizon was designed. Transition probabilities and utility values for different angina frequencies were obtained from the literature. Costs were obtained from Spanish official DRGs for patients with chronic angina pectoris. We calculated the incremental cost-utility ratio of using ranolazine compared with a placebo. Sensitivity analyses, by means of Monte Carlo simulations, were performed. Acceptability curves and expected value of perfect information were calculated.

Results

The incremental cost-utility ratio was €8,455 per quality-adjusted life-year (QALY) per patient in Spain. Sensitivity analyses showed that if the decision makers’ willingness to pay is €15,000 per QALY, the treatment with ranolazine will be cost effective at a 95 % level of confidence. The incremental cost-utility ratio is particularly sensitive to changes in utility values of those non-hospitalized patients with mild or moderate angina frequency.

Conclusions

Ranolazine is a highly efficient add-on therapy for the symptomatic treatment of chronic angina pectoris in patients who are inadequately controlled by, or intolerant to, first-line antianginal therapies in Spain.
Literature
1.
Lopez-Sendon, J.: Chronic stable angina guidelines: is there an emerging international consensus? Br J Cardiol 19(Suppl. 2), S2–S11 (2012)
2.
Boden, W.E.: Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med 356(15), 1503–1516 (2007)PubMedCrossRef
3.
Keating, G.M.: Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs 73(1), 55–73 (2013)PubMedCrossRef
4.
Brown, N., Melville, M., Gray, D., Young, T., Munro, J., Skene, A.M., et al.: Quality of life four years after acute myocardial infarction: short form 36 scores compared with a normal population. Heart 81(4), 352–358 (1999)PubMedCentralPubMedCrossRef
5.
Brorsson, B., Bernstein, S.J., Brook, R.H., Werko, L.: Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart 87(2), 140–145 (2002)PubMedCentralPubMedCrossRef
6.
Arnold, S.V., Morrow, D.A., Lei, Y., Cohen, D.J., Mahoney, E.M., Braunwald, E., et al.: Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2(4), 344–353 (2009)PubMedCrossRef
7.
Beltrame, J.F., Weekes, A.J., Morgan, C., Tavella, R., Spertus, J.A.: The prevalence of weekly angina among patients with chronic stable angina in primary care practices: the Coronary Artery Disease in General Practice (CADENCE) Study. Arch. Intern. Med 169(16), 1491–1499 (2009)PubMedCrossRef
8.
Maddox, T.M., Reid, K.J., Spertus, J.A., Mittleman, M., Krumholz, H.M., Parashar, S., et al.: Angina at 1 year after myocardial infarction: prevalence and associated findings. Arch. Intern. Med 168(12), 1310–1316 (2008)PubMedCrossRef
9.
Kosiborod, M., Arnold, S.V., Spertus, J.A., McGuire, D.K., Li, Y., Yue, P., et al.: Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects with Chronic Stable Angina). J. Am. Coll. Cardiol 61(20), 2038–2045 (2013)PubMedCrossRef
10.
11.
Alonso, J.J., Bueno, H.: Angina de pecho estable. Trascendencia clínica en la era de la intervención, limitaciones y avances actuales de su terapia farmacológica. Rev. Esp. Cardiol 7(Supl D), 9–18 (2007)
12.
Chaitman, B., Skettino, S., Parker, J., Hanley, P., Meluzin, J., Kuch, J., et al.: Anti-ischemia effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol. 43(8), 1375–1382 (2004)PubMedCrossRef
13.
Chaitman, B., Pepine, C., Parker, J., Skopal, J., Chumakova, G., Kuch, J., et al.: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA 291(3), 309–316 (2004)PubMedCrossRef
14.
Stone, P.H.G.N., Blokhin, A., et al.: Anti-anginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial. J. Am. Coll. Cardiol 48, 566–575 (2006)PubMedCrossRef
15.
Arnold, S.V., Morrow, D.A., Wang, K., Lei, Y., Mahoney, E.M., Scirica, B.M., Braunwald, E., Cohen, D.J., MERLIN-TIMI 36 Investigators: Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes 1(2), 107–115 (2008). Epub 2008 Nov 5PubMedCrossRef
16.
Morrow, D.A., Scirica, B.M., Karwatowska-Prokopczuk, E.: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 297(16), 1775–1783 (2007)PubMedCrossRef
17.
Shaw, J.W., Johnson, J.A., Coons, S.J.: US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 43(3), 203–220 (2005)PubMedCrossRef
18.
Sossalla, S., Maier, L.S.: Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther 133(3), 311–323 (2012)PubMedCrossRef
19.
Lucioni, C., Mazzi, S.: Una valutazione economica di ranolazina add-on nel trattamento dell′angina stabile cronica. Pharmaco Econ Italian Res Art 11(3), 141–152 (2009)CrossRef
20.
Karwatowska-Prokopczuk, E., Wang, W., Cheng, M.L., Zeng, D., Schwartz, P.J., Belardinelli, L.: The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine. Europace 15(3), 429–436 (2013)PubMedCrossRef
21.
Etemad, L., McCollam, P.: Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm 11, 300–306 (2005)PubMed
22.
Spertus, J.A., Winder, J.A., Dewhurst, T.A., et al.: Development and evaluation of the Seattle angina questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 25, 333–341 (1995)PubMedCrossRef
23.
Fox, K., Garcia, M.A., Ardissino, D., Buszman, P., Camici, P.G., Crea, F., et al.: Guidelines on the management of stable angina pectoris. Executive summary. Rev Esp Cardiol 59(9), 919–970 (2006)PubMedCrossRef
24.
25.
26.
Daly, C., Clemens, F., Lopez Sendon, J., Tavazzi, L., Boersma, E., Danchin, N., et al.: The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heart J 26, 1011–1022 (2005)PubMedCrossRef
27.
28.
29.
Longworth, I., Bluxton, M., Sculpher, M.: Estimating utility data from clinical indicators for patients with stable angina. Eur J Health Econ 6, 347–353 (2005)PubMedCrossRef
30.
Griffin, S., Barber, J., Manca, A.: Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. British Med J 334, 624–628 (2007)CrossRef
31.
Briggs, A., Sculpher, M., Claxton, K.: Decision modelling for health economics. Oxford University Press, Oxford (2006)
32.
Claxton,  K.: Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ 8(3), 269–274 (1999)PubMedCrossRef
33.
Sacristán, J., Oliva, J., Del Llano, J., Prieto, L., Pinto, J.: What is an efficient health technology in Spain? Gac Sanit 16(4), 334–343 (2002)PubMedCrossRef
Metadata
Title
Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain
Authors
Álvaro Hidalgo-Vega
Juan Manuel Ramos-Goñi
Renata Villoro
Publication date
01-12-2014
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 9/2014
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-013-0534-8

Other articles of this Issue 9/2014

The European Journal of Health Economics 9/2014 Go to the issue

Original Paper

Brand switching or reduced consumption? A study of how cigarette taxes affect tobacco consumption

Editorial

Analysing coverage decision-making: opening Pandora’s box?

Original Paper

Cost effects of hospital mergers in Portugal

Original Paper

Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)

Original Paper

Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs

Original Paper

The impact of ageing on health care expenditures: a study of steepening